The two faces of the 15-lipoxygenase in atherosclerosis

Paoletti, 2004, Inflammation in atherosclerosis and implications for therapy, Circulation, 109, 20

Hansson, 2005, Inflammation, atherosclerosis, and coronary artery disease, N. Engl. J. Med., 352, 1685, 10.1056/NEJMra043430

Eriksson, 2004, Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects, Curr. Opin. Lipidol., 15, 553, 10.1097/00041433-200410000-00009

Dong, 1998, The combined role of P- and E-selectins in atherosclerosis, J. Clin. Invest., 102, 145, 10.1172/JCI3001

Smith, 1995, Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E, Proc. Natl. Acad. Sci. USA, 92, 8264, 10.1073/pnas.92.18.8264

Stocker, 2004, Role of oxidative modifications in atherosclerosis, Physiol. Rev., 84, 1381, 10.1152/physrev.00047.2003

Henriksen, 1981, Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins, Proc. Natl. Acad. Sci. USA, 78, 6499, 10.1073/pnas.78.10.6499

Stary, 1994, A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association, Circulation, 89, 2462, 10.1161/01.CIR.89.5.2462

Binder, 2002, Innate and acquired immunity in atherogenesis, Nat. Med., 8, 1218, 10.1038/nm1102-1218

Stary, 1995, A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association, Circulation, 92, 1355, 10.1161/01.CIR.92.5.1355

Naghavi, 2003, From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I, Circulation, 108, 1664, 10.1161/01.CIR.0000087480.94275.97

Naghavi, 2003, From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II, Circulation, 108, 1772, 10.1161/01.CIR.0000087481.55887.C9

Makheja, 1989, Anti-inflammatory drugs in experimental atherosclerosis. 7 spontaneous atherosclerosis in WHHL rabbits and inhibition by cortisone acetate, Atherosclerosis, 76, 155, 10.1016/0021-9150(89)90099-3

Hiltunen, 1995, Induction of 15-lipoxygenase mRNA and protein in early atherosclerotic lesions, Circulation, 92, 3297, 10.1161/01.CIR.92.11.3297

Yla-Herttuala, 1990, Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions, Proc. Natl. Acad. Sci. USA, 87, 6959, 10.1073/pnas.87.18.6959

Kuhn, 1994, Involvement of 15-lipoxygenase in early stages of atherogenesis, J. Exp. Med., 179, 1903, 10.1084/jem.179.6.1903

Yla-Herttuala, 1995, Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid–protein adducts characteristic of oxidized low density lipoprotein, J. Clin. Invest., 95, 2692, 10.1172/JCI117971

Yla-Herttuala, 1991, Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts, J. Clin. Invest., 87, 1146, 10.1172/JCI115111

Kuhn, 1997, In vivo action of 15-lipoxygenase in early stages of human atherogenesis, J. Clin. Invest., 99, 888, 10.1172/JCI119253

Spanbroek, 2003, Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis, Proc. Natl. Acad. Sci. USA, 100, 1238, 10.1073/pnas.242716099

Belkner, 1993, Oxygenation of lipoproteins by mammalian lipoxygenases, Eur. J. Biochem., 213, 251, 10.1111/j.1432-1033.1993.tb17755.x

Cathcart, 1991, Lipoxygenase-mediated transformation of human low density lipoprotein to an oxidized and cytotoxic complex, J. Lipid. Res., 32, 63, 10.1016/S0022-2275(20)42244-8

Shen, 1995, Transgenic rabbits with the integrated human 15-lipoxygenase gene driven by a lysozyme promoter: macrophage-specific expression and variable positional specificity of the transgenic enzyme, FASEB J., 9, 1623, 10.1096/fasebj.9.15.8529842

Shen, 1996, Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development, J. Clin. Invest., 98, 2201, 10.1172/JCI119029

Trebus, 2002, Transient experimental anemia in cholesterol-fed rabbits induces systemic overexpression of the reticulocyte-type -lipoxygenase and protects from aortic lipid deposition, Prostaglandins Leukot. Essent. Fatty Acids, 67, 419, 10.1054/plef.2002.0452

Kuhn, 1999, The diversity of the lipoxygenase family. Many sequence data but little information on biological significance, FEBS Lett., 449, 7, 10.1016/S0014-5793(99)00396-8

Kuhn, 1993, Bacterial expression, purification and partial characterization of recombinant rabbit reticulocyte 15-lipoxygenase, Biochim. Biophys. Acta, 1168, 73, 10.1016/0005-2760(93)90268-E

Funk, 1996, The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice, Biochim. Biophys. Acta, 1304, 65, 10.1016/S0005-2760(96)00107-5

Chen, 1994, cDNA cloning, expression, mutagenesis of C-terminal isoleucine, genomic structure, and chromosomal localizations of murine 12-lipoxygenases, J. Biol. Chem., 269, 13979, 10.1016/S0021-9258(17)36743-1

Sigal, 1991, The molecular biology of mammalian arachidonic acid metabolism, Am. J. Physiol., 260, L13

Rankin, 1991, Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages, J. Lipid Res., 32, 449, 10.1016/S0022-2275(20)42068-1

Sigari, 1997, Fibroblasts that overexpress 15-lipoxygenase generate bioactive and minimally modified LDL, Arterioscler. Thromb. Vasc. Biol., 17, 3639, 10.1161/01.ATV.17.12.3639

Sakashita, 1999, Essential involvement of 12-lipoxygenase in regiospecific and stereospecific oxidation of low density lipoprotein by macrophages, Eur. J. Biochem., 265, 825, 10.1046/j.1432-1327.1999.00803.x

Folcik, 1997, Cytokine modulation of LDL oxidation by activated human monocytes, Arterioscler. Thromb. Vasc. Biol., 17, 1954, 10.1161/01.ATV.17.10.1954

Sun, 1996, Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein,, J. Biol. Chem., 271, 24055, 10.1074/jbc.271.39.24055

Huang, 1999, Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase, Nature, 400, 378, 10.1038/22572

Schild, 2002, The activity of PPAR gamma in primary human trophoblasts is enhanced by oxidized lipids, J. Clin. Endocrinol. Metab., 87, 1105, 10.1210/jc.87.3.1105

Delerive, 2000, Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner, FEBS Lett., 471, 34, 10.1016/S0014-5793(00)01364-8

Hersberger, 2003, Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment, Drugs, 63, 1907

Belkner, 2005, Expression of 12/15-lipoxygenase attenuates intracellular lipid deposition during in vitro foam cell formation, Arterioscler. Thromb. Vasc. Biol., 25, 797, 10.1161/01.ATV.0000157580.26858.2d

Belkner, 1998, The rabbit 15-lipoxygenase preferentially oxygenates LDL cholesterol esters, and this reaction does not require vitamin E, J. Biol. Chem., 273, 23225, 10.1074/jbc.273.36.23225

Zhu, 2003, Low density lipoprotein receptor-related protein-mediated membrane translocation of 12/15-lipoxygenase is required for oxidation of low density lipoprotein by macrophages, J. Biol. Chem., 278, 13350, 10.1074/jbc.M212104200

Takahashi, 2005, Selective uptake and efflux of cholesteryl linoleate in LDL by macrophages expressing 12/15-lipoxygenase, Biochem. Biophys. Res. Commun., 338, 128, 10.1016/j.bbrc.2005.07.182

Swarnakar, 2001, The apolipoprotein E-dependent low density lipoprotein cholesteryl ester selective uptake pathway in murine adrenocortical cells involves chondroitin sulfate proteoglycans and an alpha 2-macroglobulin receptor, J. Biol. Chem., 276, 21121, 10.1074/jbc.M101691200

Bradamante, 1992, Free radicals promote modifications in plasma high-density lipoprotein: nuclear magnetic resonance analysis, Free Radic. Biol. Med., 12, 193, 10.1016/0891-5849(92)90027-E

Slotte, 1990, Oxidation of cholesterol in low density and high density lipoproteins by cholesterol oxidase, J. Lipid. Res., 31, 2235, 10.1016/S0022-2275(20)42111-X

Rohrer, 2004, High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease, Curr. Opin. Lipidol., 15, 269, 10.1097/00041433-200406000-00006

Marsche, 2002, Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport, J. Biol. Chem., 277, 32172, 10.1074/jbc.M200503200

Nagano, 1991, High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification, Proc. Natl. Acad. Sci. USA, 88, 6457, 10.1073/pnas.88.15.6457

Pirillo, 2006, 15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages, Biochim. Biophys. Acta, 1761, 292, 10.1016/j.bbalip.2006.03.009

Hurtado, 1996, In vitro oxidised HDL exerts a cytotoxic effect on macrophages, Atherosclerosis, 125, 39, 10.1016/0021-9150(96)05840-6

Musanti, 1993, Interaction of oxidized HDLs with J774-A1 macrophages causes intracellular accumulation of unesterified cholesterol, Arterioscler. Thromb., 13, 1334, 10.1161/01.ATV.13.9.1334

Witztum, 1991, Role of oxidized low density lipoprotein in atherogenesis, J. Clin. Invest., 88, 1785, 10.1172/JCI115499

Reilly, 2004, 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo, J. Biol. Chem., 279, 9440, 10.1074/jbc.M303857200

Hatley, 2003, Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice, J. Biol. Chem., 278, 25369, 10.1074/jbc.M301175200

Wolle, 1996, Transient overexpression of human 15-lipoxygenase in aortic endothelial cells enhances tumor necrosis factor-induced vascular cell adhesion molecule-1 gene expression, Biochem. Biophys. Res. Commun., 220, 310, 10.1006/bbrc.1996.0402

Bolick, 2005, 12/15-Lipoxygenase regulates intercellular adhesion molecule-1 expression and monocyte adhesion to endothelium through activation of RhoA and nuclear factor-kappaB, Arterioscler. Thromb. Vasc. Biol., 25, 2301, 10.1161/01.ATV.0000186181.19909.a6

Viita, 1999, High expression of human 15-lipoxygenase induces NF-kappaB-mediated expression of vascular cell adhesion molecule 1, intercellular adhesion molecule 1, and T-cell adhesion on human endothelial cells, Antioxid. Redox Signal, 1, 83, 10.1089/ars.1999.1.1-83

Huber, 2006, Specific monocyte adhesion to endothelial cells induced by oxidized phospholipids involves activation of cPLA2 and lipoxygenase, J. Lipid. Res., 47, 1054, 10.1194/jlr.M500555-JLR200

Glass, 2001, Atherosclerosis. The road ahead,, Cell, 104, 503, 10.1016/S0092-8674(01)00238-0

Rao, 1995, Linoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-Fos, c-Jun, and c-Myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells, J. Clin. Invest., 96, 842, 10.1172/JCI118130

Natarajan, 1997, Regulation of 12-lipoxygenase by cytokines in vascular smooth muscle cells, Hypertension, 30, 873, 10.1161/01.HYP.30.4.873

Nakao, 1982, Comparative effect of lipoxygenase products of arachidonic acid on rat aortic smooth muscle cell migration, Atherosclerosis, 44, 339, 10.1016/0021-9150(82)90008-9

Taylor, 2005, The effects of leukocyte-type 12/15-lipoxygenase on Id3-mediated vascular smooth muscle cell growth, Arterioscler. Thromb. Vasc. Biol., 25, 2069, 10.1161/01.ATV.0000178992.40088.f2

Dzau, 1988, Circulating versus local renin-angiotensin system in cardiovascular homeostasis, Circulation, 77, I4

Ansell, 2005, Evidence for a combined approach to the management of hypertension and dyslipidemia, Am. J. Hypertens., 18, 1249, 10.1016/j.amjhyper.2005.03.740

Kim, 1995, A leukocyte type of 12-lipoxygenase is expressed in human vascular and mononuclear cells. Evidence for upregulation by angiotensin II, Arterioscler. Thromb. Vasc. Biol., 15, 942, 10.1161/01.ATV.15.7.942

Stanke-Labesque, 2000, Angiotensin II-induced contractions in human internal mammary artery: effects of cyclooxygenase and lipoxygenase inhibition, Cardiovasc. Res., 47, 376, 10.1016/S0008-6363(00)00112-7

Anning, 2005, Elevated endothelial nitric oxide bioactivity and resistance to angiotensin-dependent hypertension in 12/15-lipoxygenase knockout mice, Am. J. Pathol., 166, 653, 10.1016/S0002-9440(10)62287-0

Keidar, 1995, Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins, Atherosclerosis, 115, 201, 10.1016/0021-9150(94)05514-J

Scheidegger, 1997, Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway, J. Biol. Chem., 272, 21609, 10.1074/jbc.272.34.21609

Cai, 2004, Growth factors induce monocyte binding to vascular smooth muscle cells: implications for monocyte retention in atherosclerosis, Am. J. Physiol. Cell Physiol., 287, C707, 10.1152/ajpcell.00170.2004

Smith, 1993, Transmembrane signaling in human polymorphonuclear neutrophils: 15(S)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid modulates receptor agonist-triggered cell activation, Proc. Natl. Acad. Sci. USA, 90, 7270, 10.1073/pnas.90.15.7270

Takata, 1994, 15-Hydroxyeicosatetraenoic acid inhibits neutrophil migration across cytokine-activated endothelium, Am. J. Pathol., 145, 541

Takata, 1994, Remodeling of neutrophil phospholipids with 15(S)-hydroxyeicosatetraenoic acid inhibits leukotriene B4-induced neutrophil migration across endothelium, J. Clin. Invest., 93, 499, 10.1172/JCI116999

Buchanan, 1985, 13-Hydroxyoctadecadienoic acid is the vessel wall chemorepellant factor, LOX, J. Biol. Chem., 260, 16056, 10.1016/S0021-9258(17)36198-7

Buchanan, 1993, Localization of 13-hydroxyoctadecadienoic acid and the vitronectin receptor in human endothelial cells and endothelial cell/platelet interactions in vitro, Blood, 81, 3303, 10.1182/blood.V81.12.3303.bloodjournal81123303

Shu, 2000, Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells, Biochem. Biophys. Res. Commun., 267, 345, 10.1006/bbrc.1999.1968

Marx, 1998, Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro, Am. J. Pathol., 153, 17, 10.1016/S0002-9440(10)65540-X

Yamaja Setty, 1987, 13-Hydroxyoctadeca-9,11-dienoic acid (13-HODE) inhibits thromboxane A2 synthesis, and stimulates 12-HETE production in human platelets, Biochem. Biophys. Res. Commun., 148, 528, 10.1016/0006-291X(87)90908-9

Ikeda, 2000, Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2, J. Biol. Chem., 275, 33142, 10.1074/jbc.M002319200

Ricote, 1998, The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation, Nature, 391, 79, 10.1038/34178

Serhan, 1984, Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes, Proc. Natl. Acad. Sci. USA, 81, 5335, 10.1073/pnas.81.17.5335

Serhan, 1994, Lipoxin biosynthesis and its impact in inflammatory and vascular events, Biochim. Biophys. Acta, 1212, 1, 10.1016/0005-2760(94)90185-6

Gronert, 2001, Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses, Am. J. Pathol., 158, 3, 10.1016/S0002-9440(10)63937-5

Serhan, 2002, Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution, Prostaglandins Other Lipid Mediat, 68–69, 433, 10.1016/S0090-6980(02)00047-3

Lee, 1989, Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-l-methionyl-l-leucyl-l-phenylalanine, Clin. Sci. (Lond.), 77, 195, 10.1042/cs0770195

Papayianni, 1996, Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells, J. Immunol., 156, 2264, 10.4049/jimmunol.156.6.2264

Colgan, 1993, Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers, J. Clin. Invest., 92, 75, 10.1172/JCI116601

Godson, 2000, Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages, J. Immunol., 164, 1663, 10.4049/jimmunol.164.4.1663

Maddox, 1996, Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction, J. Exp. Med., 183, 137, 10.1084/jem.183.1.137

Mantovani, 2004, The chemokine system in diverse forms of macrophage activation and polarization, Trends. Immunol., 25, 677, 10.1016/j.it.2004.09.015

Mitchell, 2002, Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo, J. Am. Soc. Nephrol., 13, 2497, 10.1097/01.ASN.0000032417.73640.72

Maderna, 2005, Taking insult from injury: lipoxins and lipoxin receptor agonists and phagocytosis of apoptotic cells, Prostaglandins Leukot. Essent. Fatty Acids, 73, 179, 10.1016/j.plefa.2005.05.004

Ariel, 2005, The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering, J. Biol. Chem., 280, 43079, 10.1074/jbc.M509796200

Serhan, 2007, Resolution phases of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways, Annu. Rev. Immunol., 25, 101, 10.1146/annurev.immunol.25.022106.141647

Arita, 2005, Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1, J. Exp. Med., 20, 713, 10.1084/jem.20042031

Hong, 2003, Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation, J. Biol. Chem., 278, 14677, 10.1074/jbc.M300218200

Marcheselli, 2003, Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression, J. Biol. Chem., 278, 43807, 10.1074/jbc.M305841200

Mukherjee, 2004, Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress, Proc. Natl. Acad. Sci. USA, 101, 8491, 10.1073/pnas.0402531101

Arita, 2005, Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis, Proc. Natl. Acad. Sci. USA, 102, 7671, 10.1073/pnas.0409271102

Hartweg, 2007, Meta-analysis of the effects of n−3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes, Diabetologia, 50, 250, 10.1007/s00125-006-0486-y

Morris, 1993, Does fish oil lower blood pressure? A meta-analysis of controlled trials, Circulation, 88, 523, 10.1161/01.CIR.88.2.523

Harrison, 2005, The mechanism of action of omega-3 fatty acids in secondary prevention post-myocardial infarction, Curr. Med. Res. Opin., 21, 95, 10.1185/030079904X17956

von Schacky, 2007, Omega-3 fatty acids and cardiovascular disease, Curr. Opin. Clin. Nutr. Metab. Care, 10, 129, 10.1097/MCO.0b013e3280127af0

Harris, 2007, Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor, Pharmacol. Res., 55, 217, 10.1016/j.phrs.2007.01.013

Marchioli, 2002, Early protection against sudden death by n−3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione, Circulation, 105, 1897, 10.1161/01.CIR.0000014682.14181.F2

Wang, 2006, n−3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review, Am. J. Clin. Nutr., 84, 5, 10.1093/ajcn/84.1.5

Kang, 2000, Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids, Am. J. Clin. Nutr., 71, 202S, 10.1093/ajcn/71.1.202S

Schrepf, 2004, Immediate effects of n−3 fatty acid infusion on the induction of sustained ventricular tachycardia, Lancet, 363, 1441, 10.1016/S0140-6736(04)16105-9

Harats, 2000, Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice, Arterioscler. Thromb. Vasc. Biol., 20, 2100, 10.1161/01.ATV.20.9.2100

Cyrus, 1999, Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice, J. Clin. Invest., 103, 1597, 10.1172/JCI5897

Cyrus, 2001, Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice, Circulation, 103, 2277, 10.1161/01.CIR.103.18.2277

Huo, 2004, Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice, Circulation, 110, 2024, 10.1161/01.CIR.0000143628.37680.F6

Wittwer, 2006, Functional polymorphism in ALOX15 results in increased allele-specific transcription in macrophages through binding of the transcription factor SPI1, Hum. Mutat., 27, 387, 10.1002/humu.20328

Wittwer, 2006, Functional polymorphism in ALOX15 results in increased allele-specific transcription in macrophages through binding of the transcription factor SPI1, Hum. Mutat., 27, 78, 10.1002/humu.20273

Wittwer, 2007, The c.-292C>T promoter polymorphism increases ALOX15 activity and could be atheroprotective,, Clin. Chem. Lab. Med., 45, 487, 10.1515/CCLM.2007.103

Yamamoto, 2005, Arachidonate 12-lipoxygenases with reference to their selective inhibitors, Biochem. Biophys. Res. Commun., 338, 122, 10.1016/j.bbrc.2005.08.214